A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Hepatitis C protease inhibitors
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 27 Feb 2018 Status changed from recruiting to completed.
- 11 May 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 02 Apr 2015 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.